25 August 2021, Munich – Cardior Pharmaceuticals has closed a Series B financing round totalling EUR 64 million (USD 76 million). The round was led by Inkef Capital, supported by fellow new investors Fund+, Sunstone, Hadean Ventures and Coparion with participation from existing investors including LSP, BioMed Partners, Bristol Myers Squibb, and High-Tech Gründerfonds.
Cardior pursues a unique approach for the treatment of cardiac disease. Its lead candidate CDR132L, an antisense oligonucleotide, inhibits a specific non-coding RNA (micro-RNA-132) in the heart tissue that contributes to key hallmarks of heart disease including cardiac hypertrophy, fibrosis, impaired contractility and reduced vascularization.
Read more
